

[Request Information](#)

[Permalink](#)

## Tetracosapentaenoic Acid Treatment for AMD, Diabetic Retinopathy and Glaucoma

Tech ID: 33747 / UC Case 2023-786-0

### BRIEF DESCRIPTION

An innovative approach using tetracosapentaenoic acid to treat age-related eye disorders by replenishing critical lipids in the retina.

### FULL DESCRIPTION

Researchers at UC Irvine have developed a method using tetracosapentaenoic acid to address age-related eye disorders such as age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma. This approach focuses on increasing the production of very long chain polyunsaturated acids (VLC-PUFAs) and docosahexaenoic acid (DHA), essential lipids that diminish with age, thereby improving retinal function and vision health.

### SUGGESTED USES

- » Treatment for various age-related eye disorders
- » Supplementation for individuals with decreased VLC-PUFA and DHA production due to aging
- » Potential application in preventive treatments for populations at risk of developing age-related eye conditions

### ADVANTAGES

- » Directly increases VLC-PUFA and DHA production, essential for retina health.
- » More effective delivery method compared to oral medications.
- » Provides a direct, specific, and reproducible method to deliver the active compound to the retina.
- » Addresses the underlying cause of lipid decrease in aging retinas.

### PATENT STATUS

Patent Pending

### CONTACT

Patricia H. Chan  
patricia.chan@uci.edu  
tel: 949-824-6821.



### OTHER INFORMATION

#### CATEGORIZED AS

- » **Medical**
  - » Disease: Ophthalmology and Optometry
  - » Therapeutics

#### RELATED CASES

2023-786-0

**UCI** Beall  
Applied Innovation

5270 California Avenue / Irvine, CA  
92697-7700 / Tel: 949.824.2683



© 2024, The Regents of the University of  
California  
[Terms of use](#)  
[Privacy Notice](#)